Moleculin Reports Interim AML Trial Remission Rates of 43% and 36%
Among the first 45 randomized patients, complete remission rates were 43% and 36% in the two Annamycin arms, versus 12% with placebo. The Data Monitoring Committee recommended continuing the study without amendment.
In the first interim analysis of its pivotal Phase 2/3 AML trial, the first 45 randomized patients had complete remission rates of 43% and 36% in the two Annamycin arms, versus 12% with placebo. The Data Monitoring Committee recommended continuing the study without amendment.Material DetailsContext…